Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XmAb5871 multiple-dose study in rheumatoid arthritis
2012-003057-29Phase 2Completed
- Sponsor
- Xencor
- Start
- Sep 2012
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of obexelimab in rheumatoid arthritis (RA) (5 arms), sponsored by Xencor. Primary endpoint: Safety and tolerability. Started Sep 2012; status: completed.
02
Drugs
obexelimab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2012-003057-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003057-29.